Your session is about to expire
← Back to Search
Gene Therapy
Gene Therapy for Diastolic Heart Failure (MUSIC-HFpEF Trial)
Phase 1
Recruiting
Research Sponsored by Sardocor Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
NYHA class II or III
On oral diuretic therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 24 and week 52
Awards & highlights
MUSIC-HFpEF Trial Summary
This trial tests a gene therapy to help people with diastolic heart failure. Participants get a one-time infusion and follow-up for safety and changes in heart function. Long-term follow-up includes yearly in-person visits and biannual phone calls.
Who is the study for?
This trial is for adults with heart failure who still have a good amount of pumping function (ejection fraction ≥ 50%) and symptoms that are not the most severe. They should be able to exercise somewhat, take diuretics, and use birth control if needed. People with severe lung disease, extreme obesity, unstable conditions, major organ dysfunction or specific heart diseases like amyloidosis can't join.Check my eligibility
What is being tested?
The study tests a one-time gene therapy infusion called AAV1/SERCA2a to see if it's safe and can help the heart fill better during relaxation. Participants will receive this treatment in a special lab setting and then be monitored closely for one year with follow-ups over phone calls for four more years.See study design
What are the potential side effects?
Potential side effects may include reactions at the infusion site or allergic responses due to the body's reaction to the new gene material. Since it involves genetic therapy, there might also be unforeseen risks related to altering genes within heart muscle cells.
MUSIC-HFpEF Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My heart condition mildly or moderately affects my daily activities.
Select...
I am currently taking water pills.
MUSIC-HFpEF Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 24 and week 52
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 24 and week 52
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in pulmonary capillary wedge pressure (PCWP)
Secondary outcome measures
Change in 6 Minute Walk Distance
Change in 6 Minute Walk Test Borg scale
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score
+8 moreMUSIC-HFpEF Trial Design
1Treatment groups
Experimental Treatment
Group I: SRD-001 Gene TherapyExperimental Treatment1 Intervention
AAV1/SERCA2a 3E13 vg
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Gene therapy for heart failure, such as the one being studied to improve ventricular relaxation, works by modifying genetic material to enhance the function of proteins involved in cardiac muscle contraction and relaxation. This can help the heart fill more effectively during diastole, improving overall cardiac function.
Other common treatments include inotropes, which increase the force of heart contractions, and vasodilators, which reduce the resistance the heart must pump against, thereby improving blood flow and reducing the heart's workload. Mechanical support devices, like ventricular assist devices, can take over some of the heart's pumping function, providing relief to the failing heart.
These treatments are crucial for heart failure patients as they aim to improve symptoms, enhance quality of life, and reduce the risk of hospitalization and mortality.
Find a Location
Who is running the clinical trial?
Sardocor Corp.Lead Sponsor
2 Previous Clinical Trials
69 Total Patients Enrolled
1 Trials studying Heart Failure
57 Patients Enrolled for Heart Failure
Share this study with friends
Copy Link
Messenger